GSK Plc’s antibody treatment Jemperli (dostarlimab) for solid tumours and endometrial cancer has been given a third indication by the US Food and Drug Administration, this time as a frontline treatment for recurrent endometrial cancer. It is now authorised in combination with carboplatin and paclitaxel chemotherapy, followed by Jemperli as a single agent, for patients with endometrial cancer that is mismatch repair deficient, as shown by an FDA test. Mismatch repair deficient (dMMR) cancers are those where errors arising during DNA replication are not corrected.
